{"generic":"Efinaconazole","drugs":["Efinaconazole","Jublia"],"mono":{"0":{"id":"jycos0","title":"Generic Names","mono":"Efinaconazole"},"1":{"id":"jycos1","title":"Dosing and Indications","sub":{"0":{"id":"jycos1b4","title":"Adult Dosing","mono":"<b>Onychomycosis due to dermatophyte, Toenails:<\/b> apply TOPICALLY to affected toenails once daily for 48 weeks; completely cover the toenail, including folds, bed, hyponychium, and undersurface of toenail plate with each application "},"1":{"id":"jycos1b5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"jycos1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Onychomycosis due to dermatophyte, Toenails<br\/>"}}},"3":{"id":"jycos3","title":"Contraindications\/Warnings","sub":[{"id":"jycos3b9","title":"Contraindications","mono":"No specific contraindications or warnings have been identified.<br\/>"},{"id":"jycos3b10","title":"Precautions","mono":"No specific contraindications or warnings have been identified.<br\/>"},{"id":"jycos3b11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"jycos3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jycos5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Dermatitis, application site (2.2%), Ingrowing toenail (2.3%)<br\/>"},"6":{"id":"jycos6","title":"Drug Name Info","sub":{"0":{"id":"jycos6b17","title":"US Trade Names","mono":"Jublia<br\/>"},"2":{"id":"jycos6b19","title":"Class","mono":"<ul><li>Antifungal<\/li><li>Triazole<\/li><\/ul>"},"3":{"id":"jycos6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jycos6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jycos7","title":"Mechanism Of Action","mono":"Efinaconazole is an azole antifungal. Fungicidal activity of efinaconazole is via inhibition of fungal lanosterol 14 alfa-demethylase. Synthesis of ergosterol for fungal cell membranes is catalyzed by fungal lanosterol 14 alfa-demethylase.<br\/>"},"8":{"id":"jycos8","title":"Pharmacokinetics","sub":{"4":{"id":"jycos8b27","title":"Elimination Half Life","mono":"29.9 hours <br\/>"}}},"9":{"id":"jycos9","title":"Administration","mono":"<b>Topical<\/b><br\/><ul><li>topical use only; not for oral, ophthalmic, or intravaginal use<\/li><li>apply with the supplied integrated flow-through brush applicator to clean and dry toenail(s); after showering, bathing, or washing, allow at least 10 minutes before application<\/li><li>contents are flammable; avoid heat or flame; store bottle upright<\/li><\/ul>"},"10":{"id":"jycos10","title":"Monitoring","mono":"improvement in the signs and symptoms of onychomycosis may indicate efficacy<br\/>"},"11":{"id":"jycos11","title":"How Supplied","mono":"<b>Jublia<\/b><br\/>Topical Solution: 10 %<br\/>"},"13":{"id":"jycos13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to report persistent irritation at application site.<\/li><li>Advise patient to avoid use near heat or open flame since solution is flammable.<\/li><li>Side effects may include ingrown toenails, or application site dermatitis, vesicles, or pain.<\/li><li>Instruct patient to wait at least 10 minutes after showering, bathing, or washing before applying drug.<\/li><\/ul>"}}}